QLC 1101
Alternative Names: QLC-1101Latest Information Update: 23 May 2024
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 08 May 2024 Qilu Pharmaceutical has patent protection for QLC 1101 (NCT06403735)
- 25 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Treatment-resistant) in China (PO) (NCT06403735)